Real-World Clinical Outcomes of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

MLA

Tohru Miyagi, et al. Real-World Clinical Outcomes of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. Nov. 2020. EBSCOhost, https://doi.org/10.21203/rs.3.rs-81346/v1.

APA

Tohru Miyagi, Taiki Kamijima, Takahiro Nohara, Kouji Izumi, Satoshi Yotsuyanagi, Atsushi Mizokami, Chikashi Seto, Hideki Asahi, Kazuyoshi Shigehara, Shohei Kawaguchi, Akinobu Takano, Yoshifumi Kadono, Ryunosuke Nakagawa, Shuhei Aoyama, & Rie Fukuda. (2020). Real-World Clinical Outcomes of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. https://doi.org/10.21203/rs.3.rs-81346/v1

Chicago

Tohru Miyagi, Taiki Kamijima, Takahiro Nohara, Kouji Izumi, Satoshi Yotsuyanagi, Atsushi Mizokami, Chikashi Seto, et al. 2020. “Real-World Clinical Outcomes of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma,” November. doi:10.21203/rs.3.rs-81346/v1.